Effectiveness of dapagliflozin versus comparators on renal endpoints in the real world: A multicentre retrospective study

Gian Paolo Fadini MD1 ⚫ | Anna Solini MD2 ⚫ | Maria Laura Manca PhD3 | Giuseppe Penno3 | Adriano Gatti MD4 | Roberto Anichini MD5 | Stefano Del Prato MD3 ⚫ | Angelo Avogaro MD1 ⚫ | For The DARWIN-T2D Network*

1Department of Medicine, University of Padova, Padova, Italy
2Department of Surgical, Medical, Molecular and Critical Area Pathology, University of Pisa, Pisa, Italy
3Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy
4Metabolic Disease Unit, San Gennaro Hospital, Naples, Italy
5Diabetes Unit, Department of Internal Medicine, San Jacopo Hospital, Pistoia, Italy

Correspondence
Gian P. Fadini, MD, Associate Professor of Endocrinology, Department of Medicine, University of Padova, Via Giustiniani 2, 35128 Padova, Italy.
Email: gianpaolo.fadini@unipd.it

Funding information
The study was supported by the Italian Diabetes Society, through a grant from AstraZeneca.

Aim: To evaluate the changes in renal endpoints in type 2 diabetes patients treated with dapagliflozin versus other glucose-lowering medications in routine clinical practice.

Materials and Methods: DARWIN-T2D was a retrospective study conducted at 46 outpatient diabetes clinics in Italy. An automated software collected data on 17,285 patients who received dapagliflozin, glucagon-like peptide-1 receptor agonists, dipeptidyl peptidase-4 inhibitors, or gli-clazide, 6,751 of whom had a follow-up visit. We analysed changes in albumin excretion rate (AER) and estimated glomerular filtration rate (eGFR).

Results: Patients who received dapagliflozin (n = 473) were younger, more obese, and had a poorer glucose control than those who received a comparator (n = 2,973). After ~6 months, median (interquartile range) AER declined by 37%, from 19.5 (7.5–78.2) to 13.2 (6.5–45.0) mg/g (P < 0.0001) in the dapagliflozin group and did not change in the comparator group. After adjusting for confounders, therapy with dapagliflozin versus comparators was associated with an AER reduction of 26.4/C613.1 mg/g (P = 0.045), and eGFR (mL/min/1.73 m²) diminished by 1.1/C60.5 (P = 0.049) in the dapagliflozin group and by 0.6/C69.1 (P = 0.002) in the comparator group (P = 0.35 between groups). No patient treated with dapagliflozin versus four patients treated with comparators experienced a doubling of serum creatinine.

Conclusions: The antiproteinuric effect of dapagliflozin is confirmed here for the first time by real-world data. Despite a mild decline in eGFR, there was no evidence of clinically relevant worsening in renal function.

KEYWORDS
antidiabetic drug, dapagliflozin, database research, diabetic nephropathy, type 2 diabetes

INTRODUCTION

The effects of glucose-lowering medications (GLM) on cardiovascular and renal outcomes have become a major issue influencing therapeutic choices for type 2 diabetes (T2D). Regulatory agencies require that, in addition to lowering blood glucose, diabetes medications have a safe cardiovascular profile. During the last 3 years, a few new GLM have proved capable of protecting patients with T2D and high cardiovascular risk from major adverse cardiovascular events (MACE). Among these, the sodium-glucose co-transporter 2 inhibitors (SGLT2i) empagliflozin and canagliflozin,2,3 as well as the glucagon-like peptide-1 receptor agonists (GLP-1RA) lixisenatide and semaglutide,4,5 reduced the risk of MACE (cardiovascular death, non-fatal myocardial infarction or stroke). Strikingly, these drugs also showed evidence of renal protection, by reducing albuminuria and/or slowing the progression of chronic kidney disease (CKD).2,4,6,7

*See the Acknowledgments for composition of the DARWIN-T2D Network.
In phase III randomized controlled trials (RCTs), treatment with SGLT2i reduced albumin excretion rate (AER), and slowed the decline in estimated glomerular filtration rate (eGFR) over time. The mechanisms mediating such effects likely result from modulation of the tubular-glomerular feedback and are independent from background therapy with angiotensin converting enzyme (ACE) inhibitors.

CKD is highly prevalent in T2D and is a strong accelerator of cardiovascular risk. In the longitudinal Italian Renal Insufficiency and Cardiovascular Events (RIACE) study, higher AER and lower eGFR, even in the normal range, identified individuals with increased mortality. Other observational studies and meta-analyses show that an excess cardiovascular morbidity and mortality is linked to impaired renal function. Therefore, it has been hypothesized that kidney protection contributes to cardiovascular protection in patients treated with SGLT2i.

However, data from RCTs may suffer from a limited external transferability and their findings need to be reproduced in clinical practice. So-called “real-world studies” use data accumulated during routine clinical practice to challenge results obtained in RCTs, address broader patient populations, and find predictors of clinical response. In the present study, we retrospectively analysed the effectiveness of the SGLT2i dapagliflozin on renal endpoints (AER and eGFR) in an Italian clinical care setting.

2 | METHODS

2.1 | Study design and aims

The DApagliflozin Real World evIdENce in Type 2 Diabetes (DARWIN-T2D) was a retrospective multicentre study performed at 46 diabetic specialist outpatient clinics in Italy. Details of the rationale and design of the study have been published previously. Briefly, the study aimed to describe the baseline clinical characteristics of patients who received a new prescription of dapagliflozin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, a long-acting GLP-1RA (liraglutide or once-weekly exenatide), or gliclazide in Italian routine clinical practice, and to retrospectively evaluate the change in effectiveness parameters at the first available follow-up after 3-12 months. An automatic software program extracted data from the same electronic chart system at all centres. The following data were collected: demographics, anthropometrics, diabetes duration, blood pressure, smoking status, fasting plasma glucose, HbA1c, lipid profile, liver enzymes, AER, eGFR (CKD-EPI), history of complications, concomitant and previous GLM. AER values reported in charts as mg/l or mg/min (normal value 0-20) were multiplied by 1.5 to convert to mg/g creatinine or mg/24 h equivalent (normal value 0-30), assuming a standard urinary volume of 1500 mL.

The primary results of the study have been published previously: although dapagliflozin was initially channelled to difficult-to-treat patients, it provided significant benefits with regard to the control of glucose, body weight, and blood pressure that were in line with findings from RCTs. Owing to the massive channelling bias, it was not possible to perform a propensity score matched comparison between the groups of patients who initiated dapagliflozin and those who initiated comparators.

In the present sub-analysis of the DARWIN-T2D study, we aimed to evaluate the effects of dapagliflozin on renal endpoints (the change from baseline in AER and eGFR) and to compare them with the effects of other GLM (combined GLP-1RA, DPP-4 inhibitors, or gliclazide).

2.2 | Patient selection

Because the primary study aim was to describe the baseline clinical characteristics of patients who received dapagliflozin in clinical practice, the follow-up visit was available for only a fraction of patients. We anticipated that data on AER and eGFR would only be available at both visits for some of the patients with a follow-up visit because the guidelines do not necessarily recommend checking renal function at short intervals in all patients. We thus identified patients for whom AER was available at both visits, those for whom eGFR was available at both visits, and those for whom both AER and eGFR were available at both visits. We calculated the change in AER and eGFR as the difference from baseline to follow-up. We also calculated the changes in HbA1c, body weight and blood pressure in the subgroup of patients with available data for AER and/or eGFR at both visits.

2.3 | Statistical analysis

Normality of continuous variables was tested with the Kolmogorov-Smirnov test. Non-normal variables were log-transformed before statistical analysis. Normal variables are presented as mean ± standard deviation, whereas non-normal variables are given as median (interquartile range [IQR]). Categorical variables are summarized using percentages. Differences between the two groups of patients who received dapagliflozin or comparator GLM were analysed using the unpaired Student’s t test for continuous variables or the chi-squared test for categorical variables. Owing to the large number of comparisons, the Bonferroni correction was used to adjust for alpha inflation because of multiple testing. Significance of the change from baseline in AER and eGFR was tested using the paired Student’s t test or, if necessary, the Wilcoxon rank test. We also calculated the percentage of patients in the various categories of AER (normo-, micro-, macroalbuminuria) at baseline and at follow-up. The significance of moving along AER categories was tested using the Wilcoxon rank test. A multiple regression analysis was used to adjust the effects of dapagliflozin versus those of comparator GLM on renal endpoints. Covariates were selected as those being significantly different between the two groups after Bonferroni correction. Variables with missing data were handled with a multiple imputation (MI) procedure using the Monte Carlo Markov Chain (MCMC) method and n = 20 imputations. The Pearson’s r coefficient was used to test linear correlations between the change in AER (log-transformed) or eGFR and clinical characteristics, as well as the change in other effectiveness variables. In addition, to detect clinical response patterns, we used random forests (RF) and partial least squares (PLS) algorithms with change in AER (log-transformed) as the dependent variable (see the File S1 for this article for further details). The statistical significance level was set at 0.05. SPSS ver. 23 and R ver. 3.5.0 were used.
RESULTS

3.1 Characteristics of study patients

Of the 2484 patients identified at baseline and who started dapagliflozin, 830 had an available follow-up visit during the observation period. Of these, 497 (60.0%) had at least one renal endpoint available both at the baseline and follow-up visits; \( n = 273 \) patients had valid AER data at both visits, \( n = 393 \) patients had valid eGFR values at both visits, and \( n = 169 \) patients had both endpoints available at both visits. Of the 14,801 patients in the comparator group who were evaluated at baseline, 5921 had a follow-up visit and 2973 (50.2%) had AER and/or eGFR available at both visits (\( n = 2277 \) for eGFR, \( n = 1380 \) for AER, \( n = 684 \) for both) (Figure 1).

Clinical characteristics of the two groups are compared in Table 1: variables that remained significantly different after Bonferroni correction were age, BMI, diastolic blood pressure, fasting plasma glucose, baseline HbA1c, triglycerides, concomitant use of metformin, insulin, and diuretics, and prevalence of microangiopathy. Extended data are available in Table S1 (see the File S1 for this article).

To evaluate selection bias, we compared the 3470 patients with and the 3281 patients without follow-up data for renal endpoints: variables with a standardized difference > 0.1 (indicating imbalance) were age, diabetes duration, LDL cholesterol and statin use, baseline eGFR, and microangiopathy (Table S2).

3.2 Change in renal endpoints during therapy with dapagliflozin versus comparators

The change in AER was examined in 273 patients who received dapagliflozin and in 1380 patients who received a comparator (Table 2). During therapy with dapagliflozin, median (IQR) AER declined from 19.5 (7.5-78.2) to 13.2 (6.5-45.0) mg/g (\( P < 0.0001 \)), equivalent to a 37% reduction (Figure 2A). The average ± SEM AER change was \(-39.3 ± 14.8\) mg/g. Significant decreases in AER occurred only in patients with micro- or macroalbuminuria, but not in patients with normoalbuminuria at baseline (Figure 2B, D).

In patients who received a comparator, overall AER did not change significantly from baseline to follow-up (average ± SEM change \(-5.9 ± 4.1\) mg/g; \( P = 0.156 \)), although it declined in those with baseline macroalbuminuria. The change in AER was significantly greater during therapy with dapagliflozin than with comparators, especially for patients with micro/macroalbuminuria at baseline (Table 2). During therapy with dapagliflozin, AER declined significantly both in patients with and in those without ongoing therapy with ACE inhibitors (ACEI) or angiotensin receptor blockers (ARBs), while AER did not change significantly in the comparator group, irrespective of therapy with ACEI/ARBs. The change from baseline in AER in patients on ACEI/ARBs was significantly greater during therapy with dapagliflozin than comparators. Dapagliflozin reduced AER irrespectively of baseline eGFR (< or > 90 mL/min/1.73 m²) and significantly more than comparators in patients with eGFR <90 mL/min/1.73 m² (Table 2).
After adjusting for baseline differences between the two groups with a multiple regression analysis, therapy with dapagliflozin remained associated with a significantly greater reduction in AER than therapy with comparators (−26.4 ± 13.1 mg/g; \(P = 0.045\)) (Table 3).

According to AER categories, 12.8% of patients in the dapagliflozin group and 10.9% in the comparator group regressed to a lower AER class, whereas 4.4% in the dapagliflozin group and 8.3% in the comparator group progressed to a higher class, for a net improvement of 8.4% in the dapagliflozin group versus 2.6% in the comparator group (\(P < 0.001\)) (Figure S1).

The change in eGFR was analysed in 393 patients in the dapagliflozin group and 2277 patients in the comparator group. During therapy with dapagliflozin, mean \(\pm SD\) eGFR declined from 87.5 ± 16.3 to 86.5 ± 17.8 mL/min/1.73 m\(^2\) (\(P = 0.049\)), with a reduction of 1.1 mL/min/1.73 m\(^2\). During therapy with a comparator, eGFR declined from 79.2 ± 18.8 to 78.6 ± 19.1 mL/min/1.73 m\(^2\) (\(P = 0.002\)), equivalent to a reduction of 0.6 mL/min/1.73 m\(^2\). The change from baseline in eGFR between the two groups was not significantly different (\(P = 0.35\)). No patient in the dapagliflozin group versus 4 patients in the comparator group exhibited a doubling of serum creatinine; no patient in the dapagliflozin group versus 11 patients in the comparator group exhibited a decline of >40% in eGFR (both not significantly different between groups).

### 3.3 Overall effectiveness of dapagliflozin and comparators

Effectiveness of dapagliflozin and comparators on glucose control, blood pressure and body weight has already been described in the total cohort of patients with a follow-up examination.\(^{20}\) In the present subgroups, HbA1c declined by 0.8 ± 1.2% in the dapagliflozin group (\(n = 490\)) and 0.6 ± 1.1% in the comparator group (\(n = 2899\)); body...
weight decreased by 2.9 ± 3.5 kg in the dapagliflozin group (n = 456) and 0.6 ± 3.3 kg in the comparator group (n = 2631); systolic blood pressure declined by 3.3 ± 17.5 mm Hg in the dapagliflozin group (n = 336) and 0.2 ± 19.4 mm Hg in the comparator group (n = 1972).

Because there was no correlation between the changes in HbA1c and systolic blood pressure (SBP) (r = 0.04; P = 0.100), in an exploratory analysis we selected patients who experienced a below median response in HbA1c and an above median response in SBP: in an exploratory analysis we selected patients who experienced a below median response in HbA1c and an above median response in SBP. In this real-world study, T2D patients initiating dapagliflozin experienced a significant reduction in AER at the first follow-up visit, on average ~6 months after baseline. Remarkably, a similar effect was not observed with comparator GLM. While a mild and marginally significant decline in eGFR was observed during dapagliflozin use, there was no evidence of clinically meaningful impairment in renal function. These results are extremely consistent with findings from phase III

3.4 | Predictors of improvement in AER

To detect predictors of AER decline in patients who received dapagliflozin, we first analysed linear correlations: the change in AER was inversely related to change in eGFR (r = −0.17; P = 0.024; n = 169), but not to the change in other efficacy variables (HbA1c, blood pressure and body weight). Thus, we used two complementary non-linear approaches: random forests and PLS (Table S3). Variables detected by RF were, in order of importance, HDL, LDL, diastolic blood pressure, triglycerides, total cholesterol, SBP and disease duration. According to PLS, only baseline AER, HbA1c and diastolic blood pressure had a significant impact.

4 | DISCUSSION

In this real-world study, T2D patients initiating dapagliflozin experienced a significant reduction in AER at the first follow-up visit, on average ~6 months after baseline. Remarkably, a similar effect was not observed with comparator GLM. While a mild and marginally significant decline in eGFR was observed during dapagliflozin use, there was no evidence of clinically meaningful impairment in renal function. These results are extremely consistent with findings from phase III
In RCTs, dapagliflozin consistently reduced AER by 36-40%\textsuperscript{8,9} irrespective of therapy with ACE inhibitors or ARBs.\textsuperscript{10} In our study, AER declined by 37% in patients taking, and by 45% in patients not taking ACEi/ARBs. The antiproteinuric effects of dapagliflozin are probably largely independent of glucose control, as patients who experienced a decline in SBP with no decline in HbA1c showed an AER reduction quantitatively similar to the entire cohort, while the same was not observed in patients taking other GLM. This observation is consistent with the supposed direct renal effect of SGLT2i via reactivation of the tubular-glomerular feedback.\textsuperscript{23}

Owing to the non-randomized nature of the comparison between treatments, the analysis of AER response predictors was performed only in the dapagliflozin group. The change in eGFR emerged as the sole linear predictor, but it explained <3% of AER variation. Non-linear approaches identified blood pressure, lipid profile, HbA1c and disease duration as variables that impacted the ability of dapagliflozin to lower AER. While triglycerides have already been associated with diabetic nephropathy,\textsuperscript{24}–\textsuperscript{26} it is remarkable that cholesterol levels modulated the renal effects of SGLT2i.

In RCTs, dapagliflozin therapy was associated with an initial drop in eGFR, followed by eGFR stabilization, such that, after 2 years of treatment, eGFR was significantly higher than in placebo-treated patients.\textsuperscript{27} The mild decline in eGFR we observe at ~6 months after initiation of dapagliflozin is consistent with RCTs and the change in eGFR during dapagliflozin was not significantly different than during therapy with comparators. Our data are also particularly reassuring on the risk that SGLT2i may acutely worsen renal function. Postmarketing pharmacovigilance has identified cases of acute kidney injury (AKI) in patients taking SGLT2i.\textsuperscript{28,29} probably because of alterations of renal function.

### TABLE 3  Results of the multiple regression analysis

| Variable                        | B ± SEM | P       |
|---------------------------------|---------|---------|
| Dapagliflozin (vs. comparators) | −26.42 ± 13.14 | 0.045   |
| Age, y                          | 0.39 ± 0.57 | 0.497   |
| BMI, kg/m\(^2\)                 | 0.49 ± 0.86 | 0.564   |
| Diastolic blood pressure, mm Hg | −0.36 ± 0.47 | 0.444   |
| Fasting plasma glucose, mg/dL   | −0.45 ± 0.18 | <0.001  |
| HbA1c, %                        | −4.14 ± 5.02 | 0.410   |
| Triglycerides, mg/dL            | 0.02 ± 0.04 | 0.585   |
| SGPT, U/L                       | 0.12 ± 0.24 | 0.618   |
| eGFR, mL/min/1.73 m\(^2\)       | 0.33 ± 0.29 | 0.251   |
| Insulin use (yes vs. no)        | −2.80 ± 11.4 | 0.806   |
| Metformin use (yes vs. no)      | 24.50 ± 13.27 | 0.065   |
| Diuretic use (yes vs. no)       | −7.19 ± 11.16 | 0.520   |
| Microangiopathy (yes vs. no)    | −17.61 ± 8.80 | 0.045   |

Change in AER was the dependent variable, whereas covariates were selected as variables that remained different between the two groups after Bonferroni correction (see Table 1).

RCTs and confirm that dapagliflozin exerts beneficial effects on the kidney. Because renal protection can contribute to cardiovascular protection, we argue that these data lend support to the potential cardiovascular efficacy of dapagliflozin. While awaiting for results of the dedicated cardiovascular outcome trial,\textsuperscript{21} registry studies indicate that dapagliflozin can protect from cardiovascular events similarly to other SGLT2i.\textsuperscript{22}
AER are expected to be rapid,8 a longer observation will be needed to acute changes in renal endpoints. While the effects of dapagliflozin on follow-up duration was short (~6 months), only allowing an analysis of observational study is not comparable to that of an RCT. Third, was inefficient and adjustment was performed using multiple regression. Thus, the degree of evidence that can be inferred from this was inefficient and adjustment was performed using multiple regression. Thus, the degree of evidence that can be inferred from this observational study is not comparable to that of an RCT. Third, follow-up duration was short (~6 months), only allowing an analysis of acute changes in renal endpoints. While the effects of dapagliflozin on AER are expected to be rapid,8 a longer observation will be needed to evaluate benefits over time and trends in eGFR. The fact that AER did not decline in the comparator group must also be interpreted in view of the short follow-up, because GLP-1RA and DPP-4 inhibitors may take longer to reduce AER.34,35 Finally, the sample size was small: less than 60% of patients had AER and/or eGFR available at both visits. This was not surprising, because eGFR and AER are not routinely checked at short intervals in all patients, but it suggests that selection bias cannot be ruled out and generalizability should be considered with caution.

In summary, this is the first real-world study confirming that a short-term treatment with the SGLT2i dapagliflozin reduces albuminuria and does not cause a clinically meaningful worsening in renal function. Although longer and larger studies may be needed to establish whether these benefits persist over time in the real world, our study supports the validity and importance of registry interrogation to determine transferability of RCT data to the clinical setting.

ACKNOWLEDGMENTS

We wish to thank Alessia Russo, Italian Diabetes Society, for the invaluable technical support. The study was supported by the Italian Diabetes Society, through a grant from AstraZeneca. The external sponsor had no role in study design, data analysis and interpretation, and decision to publish.

Composition of the DARWIN-T2D database

Agostino Consoli and Gloria Formoso (Dipartimento di Medicina e Scienze dell’Invecchiamento - Università Degli studi G. D’Annunzio di Chieti-Pescara); Giovanni Grossi (Ospedale San Francesco di Paola - Azienda Sanitaria Provinciale di Cosenza); Achirpita Pucci (Azienda Sanitaria Provinciale di Cosenza); Giorgio Sesti and Francesco Andreozzi (Azienda Ospedaliero Universitaria di Catanazzo); Giuseppe Capobianco (Azienda Sanitaria Locale Napoli 2 Nord); Adriano Gatti (Ospedale San Gennaro dei Poveri - Azienda Sanitaria Locale Napoli 1 Centro); Riccardo Bonadonna, Ivana Zavaroni and Alessandra Dei Cas (Azienda Ospedaliero Universitaria di Parma); Giuseppe Felace (Ospedale di Spilimbergo - Azienda per l’Assistenza Sanitaria n.5 Friuli Occidentale); Patrizia Li Volsi (Ospedale di Pordenone - Azienda per l’Assistenza Sanitaria n.5 Friuli Occidentale); Raffaella Buzzetti and Gaetano Leto (Ospedale Santa Maria Goretti - Azienda Sanitaria Locale di Latina); Gian Pio Sorice (Fondazione Policlinico Universitario A. Gemelli, Roma); Paola D’Angelo (Ospedale Sandro Pertini - Azienda Sanitaria Locale Roma 2); Susanna Morano (Azienda Ospedaliera Universitaria Policlinico Umberto I, Roma); Antonio Carlo Bossi (Ospedale di Treviso - Azienda Socio Sanitaria Territoriale Bergamo Ovest); Edoardo Duratorre (Ospedale Luini Confalonieri di Luino - Azienda Socio Sanitaria Territoriale Sette Laghi); Ivano Franzetti (Ospedale Sant’Antonio Abate di Gallarate - Azienda Socio Sanitaria Territoriale Valle Olona); Paola Silvia Morpurgo (Ospedale Fatebenefratelli - Azienda Socio Sanitaria Territoriale Fatebenefratelli Sacco); Emanuela Orsi (Fondazione IRCCS Ca’ Granda – Ospedale Maggiore Policlinico di Milano); Fabrizio Querci (Ospedale Pesenti Faral von Alzano Lombardo - Azienda Socio Sanitaria Territoriale Bergamo Est); Massimo Boemi and Federica D’Angelo (Presidio Ospedaliero di Ricerca INRCA-IRCCS di Ancona); Massimiliano Petrelli (Azienda Ospedaliero Universitaria Ospedali Riuniti di Ancona); Gianluca Almaretta and Ioannis Karamouzis (Azienda Ospedaliero Universitaria Maggiore della Carità di Novara); Franco Cavalot (Azienda Ospedaliero Universitaria San Luigi Gonzaga, Orbassano); Giuseppe Saglietti (Ospedale Madonna del Popolo di Omegna - Azienda Sanitaria Locale Verbano Cusio Ossola); Giuliana Cazzetta (Casa della Salute. Ugento - Distretto Socio Sanitario Gagliano del Capo - Azienda Sanitaria Locale di Lecce); Silvestre Cervone (Presidio ospedaliero San Marco in Lamis - Distretto Socio Sanitario San Marco in Lamis - Azienda Sanitaria Locale di Foglia); Eleonora Devangelio (Distretto Socio Sanitario di Massafra - Azienda Sanitaria Locale di Taranto); Olga Lamacchia (Azienda Ospedaliero Universitaria Ospedali Riuniti di Foggia); Salvatore Arena (Ospedale Umberto I - Azienda Sanitaria Provinciale di Siracusa); Antonino Di Benedetto (Azienda Ospedaliero Universitaria Policlinico G. Martino di Messina); Lucia Frittitta (Azienda Ospedaliera di Rilievo Nazionale e di Alta Specializzazione Garibaldi di Catania); Carla Giordano (Azienda Universitaria Policlinico Paolo Giaccone di Palermo); Salvatore Piro (Azienda Ospedaliera di Rilievo Nazionale e di Alta Specializzazione Garibaldi di Catania); Manfredi Rizzo, Roberta Chianetta and Carlo Mannina (Azienda Universitaria Policlinico Paolo Giaccone di Palermo); Roberto Anichini (Ospedale San Jacopo di Pistoia - Azienda USL Toscana Centro); Giuseppe Penno (Azienda Ospedaliero Universitaria Pisana); Anna Solini (Azienda Ospedaliera Universitaria Pisana); Bruno Fattor (Comprensorio Sanitario di Bolzano - Azienda Sanitaria della Provincia Autonoma di Bolzano); Enzo Bonora and Massimo Cigolini (Azienda Ospedaliero Universitaria Integrata di Verona); Annunziata Lapolla and Nino Cristiano Chieelli (Complesso Socio Sanitario Ai Colli - Azienda ULSS n.6 Euganea); Maurizio Poli (Ospedale Girolamo Fracastoro di San Bonifacio - Azienda ULSS n.9 Scaligera); Natalino Simioni and Vera Frison (Ospedale di Cittadella - Azienda ULSS n.6 Euganea); Carmela Vinci (Azienda ULSS n.4 Veneto Orientale).
REFERENCES

1. Avogaro A, Fadini GP, Sesti G, Bonora E, Del Prato S. Continued efforts to translate diabetes cardiovascular outcome trials into clinical practice. *Cardiovasc Diabetol*. 2016;15:111.

2. Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. *N Engl J Med*. 2017;377:644-657.

3. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. *N Engl J Med*. 2015;373:2117-2128.

4. Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. *N Engl J Med*. 2016;375:1834-1844.

5. Marso SP, Daniels GH, Brown-Grant K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. *N Engl J Med*. 2016;375:311-322.

6. Mann JFE, Orsted DD, Brown-Grant K, et al. Liraglutide and renal outcomes in type 2 diabetes. *N Engl J Med*. 2017;377:839-848.

7. Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. *N Engl J Med*. 2016;375:323-334.

8. Dekkers CCJ, Petrykiv S, Lavernier GD, Cheyne DZ, Gansevoort RT, Heerspink HJL. Effects of the SGLT-2 inhibitor dapagliflozin on glomerular and tubular injury markers. *Diabetes Obes Metab*. 2018;20:1988-1993.

9. Petrykiv S, Lavernier GD, de Zeeuw D, Heerspink HJL. The albuminuria-lowering response to dapagliflozin is variable and reproducible among individual patients. *Diabetes Obes Metab*. 2017;19:1363-1370.

10. Heerspink HJ, Johnsson E, Gause-Nilsson I, Cain VA, Sjostrom CD. Dapagliflozin reduces albuminuria in patients with diabetes and hypertension receiving renin-angiotensin blockers. *Diabetes Obes Metab*. 2016;18:590-597.

11. Hamada S, Guilford MC. Multiple risk factor control, mortality and cardiovascular events in type 2 diabetes and chronic kidney disease: a population-based cohort study. *BMJ Open*. 2018;8:e019950.

12. Penno G, Solini A, Bonora E, et al. Defining the contribution of chronic kidney disease to all-cause mortality in patients with type 2 diabetes: the renal insufficiency and cardiovascular events (RIACE) Italian multicenter study. *Acta Diabetol*. 2018;55:603-612.

13. Cea Soriano L, Johannson S, Stefansson B, Rodríguez LA. Cardiovascular events and all-cause mortality in a cohort of 57,946 patients with type 2 diabetes: associations with renal function and cardiovascular risk factors. *Cardiovasc Diabetol*. 2015;14:38.

14. Fox CS, Matsushita K, Woodward M, et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis. *Lancet*. 2012;380:1662-1673.

15. Perrone-Filardi P, Avogaro A, Bonora E, et al. Mechanisms linking empagliflozin to cardiovascular and renal protection. *Int J Cardiol*. 2017;241:450-456.

16. Heerspink HJ, Perkins BA, Fitchett DH, Husain M, Cherner DZ. Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications. *Circulation*. 2016;134:752-772.

17. Frieden TR. Evidence for health decision making - beyond randomized, controlled trials. *N Engl J Med*. 2017;377:465-475.

18. Patel A, Billot L. Reality and truth: balancing the hope and the hype of real-world evidence. *Circulation*. 2017;136:260-262.

19. Fadini GP, Zatti G, Consoli A, Bonora E, Sesti G, Avogaro A. Rationale and design of the DARWIN-T2D (Dapagliflozin real world eviNce in type 2 diabetes): a multicenter retrospective nationwide Italian study and crowdfunding opportunity. *Nutr Metab Cardiovasc Dis*. 2017;27:1089-1097.

20. Raz I, Mosenzon O, Bonaca MP, et al. DECLARE-TIMI 58: Participants’ baseline characteristics. *Diabetes Obes Metab*. 2018;20:1102-1110.

21. Birkeland KI, Jorgensen ME, Carstensen B, et al. Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CRED-REAL Nordic): a multinational observational analysis. *Lancet Diabetes Endocrinol*. 2017;5:709-717.

22. Cherney DZ, Perkins BA, Soleymanlou N, et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. *Circulation*. 2014;129:587-597.

23. Retnakaran R, Cull CA, Thorne KI, Adler AI, Holman RR. Risk factors for renal dysfunction in type 2 diabetes: U.K. prospective diabetes study 74. *Diabetes*. 2006;55:1832-1839.

24. Penno G, Solini A, Zoppini G, et al. Rate and determinants of association between advanced retinopathy and chronic kidney disease in patients with type 2 diabetes: the renal insufficiency and cardiovascular events (RIACE) Italian multicenter study. *Diabetes Care*. 2012;35:2317-2323.

25. Russo GT, De Cosmo S, Viazzi F, et al. Plasma triglycerides and HDL-C levels predict the development of diabetic kidney disease in subjects with type 2 diabetes: the AMD annals initiative. *Diabetes Care*. 2016;39:2278-2287.

26. Kohan DE, Fioretto P, Johnsson K, Parikh S, Ptaszynska A, Ying L. The effect of dapagliflozin on renal function in patients with type 2 diabetes. *J Nephrol*. 2016;29:391-400.

27. Perlman A, Heyman SN, Matok I, Stokar J, Muszkat M, Szalat A. Acute renal failure with sodium-glucose-cotransporter-2 inhibitors: analysis of the FDA adverse event report system database. *Nutr Metab Cardiovasc Dis*. 2017;27:1108-1113.
29. Desai M, Yavin Y, Balis D, et al. Renal safety of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2017;19:897-900.

30. Szalat A, Perlman A, Muszkat M, Khamaisi M, Abassi Z, Heyman SN. Can SGLT2 inhibitors cause acute renal failure? Plausible role for altered glomerular hemodynamics and medullary hypoxia. Drug Saf. 2018;41:239-252.

31. Hahn K, Ejaz AA, Kanbay M, Lanaspa MA, Johnson RJ. Acute kidney injury from SGLT2 inhibitors: potential mechanisms. Nat Rev Nephrol. 2016;12:711-712.

32. Nadkami GN, Ferrandino R, Chang A, et al. Acute kidney injury in patients on SGLT2 inhibitors: a propensity-matched analysis. Diabetes Care. 2017;40:1479-1485.

33. Pugliese G, Solini A, Fondelli C, et al. Reproducibility of albuminuria in type 2 diabetic subjects. Findings from the renal insufficiency and cardio-vascular events (RIACE) study. Nephrol Dial Transplant. 2011;26:3950-3954.

34. Avgerinos I, Karagiannis T, Malandris K, et al. Glucagon-like peptide 1 receptor agonists and microvascular outcomes in type 2 diabetes: a systematic review and meta-analysis. Diabetes Obes Metab. 2018 [published online ahead of print 29. https://doi.org/10.1111/dom.13484].

35. Avogaro A, Fadini GP. The effects of dipeptidyl peptidase-4 inhibition on microvascular diabetes complications. Diabetes Care. 2014;37:2884-2894.

SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section at the end of the article.

How to cite this article: Fadini GP, Solini A, Manca ML, et al. Effectiveness of dapagliflozin versus comparators on renal endpoints in the real world: A multicentre retrospective study. Diabetes Obes Metab. 2019;21:252–260. https://doi.org/10.1111/dom.13508